drugset / Trial / NCT01860404
BCAA Supplementation for Concussion
Phase 2
Completed
42 enrolled
Children's Hospital of Philadelphia
Main Line Health · collabPennsylvania Department of Health · collabThe Dana Foundation · collabUniversity of Pennsylvania · collab
RandomizedParallel-groupQuadruple-blindTreatment
Summary
This study is a randomized, placebo-controlled, double-blinded, therapeutic exploratory clinical trial of branched chain amino acids (BCAA's) in the treatment of concussion. The aim of the study is to determine whether, compared to placebo treatment, administration of BCAA's, at one or more doses, after a concussion improves neurocognitive recovery at one or more time-periods post concussion.
Timeline
- Start
- 2014-01
- Primary completion
- 2023-01
- Completion
- 2023-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Branched-Chain Amino Acids | Other / unclassified | 7.5 g | — |
| Subject | Branched-Chain Amino Acids | Other / unclassified | 15 g | — |
| Subject | Branched-Chain Amino Acids | Other / unclassified | 22.5 g | — |
| Subject | Branched-Chain Amino Acids | Other / unclassified | 27 g | — |